CoChat
Sign Up
Cited by 118Mesenchymal stem cell researchT-cell and B-cell ImmunologyHematopoietic Stem Cell Transplantation

Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance

Open access
Negi, Neema, Griffin, Matthew D.·2020·Stem Cells
DOI 10.1002/stem.3151PMC PMC7217190
Open this paper in CoChat — free accountOpen PDF

Abstract

The immunomodulatory potential of mesenchymal stromal cells (MSCs) and regulatory T cells (T-reg) is well recognized by translational scientists in the field of regenerative medicine and cellular therapies. A wide range of preclinical studies as well as a limited number of human clinical trials of MSC therapies have not only shown promising safety and efficacy profiles but have also revealed changes in T-reg frequency and function. However, the mechanisms underlying this potentially important observation are not well understood and, consequently, the optimal strategies for harnessing MSC/T-reg cross-talk remain elusive. Cell-to-cell contact, production of soluble factors, reprogramming of antigen presenting cells to tolerogenic phenotypes, and induction of extracellular vesicles (“exosomes”) have emerged as possible mechanisms by which MSCs produce an immune-modulatory milieu for T-reg expansion. Additionally, these two cell types have the potential to complement each other's immunoregulatory functions, and a combinatorial approach may exert synergistic effects for the treatment of immunological diseases. In this review, we critically assess recent translational research related to the outcomes and mechanistic basis of MSC effects on T-reg and provide a perspective on the potential for this knowledge base to be further exploited for the treatment of autoimmune disorders and transplants.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/stem.3151

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Through IL-10, PD-1, and PGE2, mesenchymal stem cells prevent T cell development into T helper 1 and T helper 17 (pro-inflammatory) cells.

    “Through IL-10, PD-1, and PGE2, MSCs prevent T cell development into T helper (Th)1 and Th17 (pro-inflammatory) cells [85, 86].”

    From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [86]

    In “Potential mechanisms for MSC-mediated effects on T-reg” (page unavailable), the review reports that MSC coculture increased regulatory T cells and decreased Th17 cell numbers, with PGE2 among the factors produced. It also describes suppression of other T-cell subsets more generally, but does not establish that IL-10, PD-1, and PGE2 together prevent differentiation into both Th1 and Th17 cells. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 88 · Cited by 118

Research works printed but not linked: 84

  1. [1]Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4): 315‐ 317. 16923606
  2. [2]Galipeau J, Sensebe L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018; 22(6): 824‐ 833. 29859173 PMC6434696
  3. [3]Yin JQ, Zhu J, Ankrum JA. Manufacturing of primed mesenchymal stromal cells for therapy. Nat Biomed Eng. 2019; 3(2): 90‐ 104. 30944433
  4. [5]Lukomska B, Stanaszek L, Zuba‐Surma E, et al. Challenges and controversies in human mesenchymal stem cell therapy. Stem Cells Int. 2019; 2019: 9628536. 31093291 PMC6481040
  5. [6]Di Ianni M, Del Papa B, De Ioanni M, et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol. 2008; 36(3): 309‐ 318. 18279718
  6. [7]Engela AU, Baan CC, Dor FJ, et al. On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front Immunol. 2012; 3: 126. 22629256 PMC3355477
  7. [8]Dai YY, Ni SY, Ma K, et al. Stem cells from human exfoliated deciduous teeth correct the immune imbalance of allergic rhinitis via Treg cells in vivo and in vitro. Stem Cell Res Ther. 2019; 10(1): 39. 30670101 PMC6341645
  8. [9]Kadle RL, Abdou SA, Villarreal‐Ponce AP, et al. Microenvironmental cues enhance mesenchymal stem cell‐mediated immunomodulation and regulatory T‐cell expansion. PLoS One. 2018; 13(3): e0193178. 29513756 PMC5841747
  9. [10]Guo L, Lai P, Wang Y, et al. Extracellular vesicles from mesenchymal stem cells prevent contact hypersensitivity through the suppression of Tc1 and Th1 cells and expansion of regulatory T cells. Int Immunopharmacol. 2019; 74: 105663. 31200338
  10. [11]Perico N, Casiraghi F, Todeschini M, et al. Long‐term clinical and immunological profile of kidney transplant patients given mesenchymal stromal cell immunotherapy. Front Immunol. 2018; 9: 1359. 29963053 PMC6014158
  11. [12]Sharabi A, Tsokos MG, Ding Y, et al. Regulatory T cells in the treatment of disease. Nat Rev Drug Discov. 2018; 17(11): 823‐ 844. 30310234
  12. [13]Liu W, Putnam AL, Xu‐Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006; 203(7): 1701‐ 1711. 16818678 PMC2118339
  13. [14]Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009; 30(6): 899‐ 911. 19464196
  14. [15]Gu J, Ni X, Pan X, et al. Human CD39(hi) regulatory T cells present stronger stability and function under inflammatory conditions. Cell Mol Immunol. 2017; 14(6): 521‐ 528. 27374793 PMC5518817
  15. [16]Mason GM, Lowe K, Melchiotti R, et al. Phenotypic complexity of the human regulatory T cell compartment revealed by mass cytometry. J Immunol. 2015; 195(5): 2030‐ 2037. 26223658
  16. [17]Nam Y, Jung SM, Rim YA, et al. Intraperitoneal infusion of mesenchymal stem cell attenuates severity of collagen antibody induced arthritis. PLoS One. 2018; 13(6): e0198740. 29879214 PMC5991665
  17. [18]Roux C, Saviane G, Pini J, et al. Immunosuppressive mesenchymal stromal cells derived from human‐induced pluripotent stem cells induce human regulatory T cells in vitro and in vivo. Front Immunol. 2017; 8: 1991. 29422893 PMC5788894
  18. [19]Lohan P, Murphy N, Treacy O, et al. Third‐party allogeneic mesenchymal stromal cells prevent rejection in a pre‐sensitized high‐risk model of corneal transplantation. Front Immunol. 2018; 9: 2666. 30515159 PMC6255848
  19. [20]Bai M, Zhang L, Fu B, et al. IL‐17A improves the efficacy of mesenchymal stem cells in ischemic‐reperfusion renal injury by increasing Treg percentages by the COX‐2/PGE2 pathway. Kidney Int. 2018; 93(4): 814‐ 825. 29132705
  20. [21]Engela AU, Baan CC, Peeters AM, et al. Interaction between adipose tissue‐derived mesenchymal stem cells and regulatory T‐cells. Cell Transplant. 2013; 22(1): 41‐ 54. 22472599
  21. [22]Prevosto C, Zancolli M, Canevali P, et al. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell‐lymphocyte interaction. Haematologica. 2007; 92(7): 881‐ 888. 17606437
  22. [23]Shi M, Liu Z, Wang Y, et al. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection. Stem Cells Translational Medicine. 2017; 6(12): 2053‐ 2061. 29178564 PMC5702514
  23. [24]Pers YM, Quentin J, Feirreira R, et al. Injection of adipose‐derived stromal cells in the knee of patients with severe osteoarthritis has a systemic effect and promotes an anti‐inflammatory phenotype of circulating immune cells. Theranostics. 2018; 8(20): 5519‐ 5528. 30555561 PMC6276295
  24. [25]Erpicum P, Weekers L, Detry O, et al. Infusion of third‐party mesenchymal stromal cells after kidney transplantation: a phase I‐II, open‐label, clinical study. Kidney Int. 2019; 95(3): 693‐ 707. 30528263
  25. [26]Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow‐derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut. 2011; 60(6): 788‐ 798. 21257987
  26. [27]Karussis D, Karageorgiou C, Vaknin‐Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010; 67(10): 1187‐ 1194. 20937945 PMC3036569
  27. [28]Wang D, Huang S, Yuan X, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2017; 14(5): 423‐ 431. 26435067 PMC5423084
  28. [29]Liang J, Zhang H, Hua B, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010; 69(8): 1423‐ 1429. 20650877
  29. [30]Zhao K, Lou R, Huang F, et al. Immunomodulation effects of mesenchymal stromal cells on acute graft‐versus‐host disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015; 21(1): 97‐ 104. 25300866
  30. [31]Ghoryani M, Shariati‐Sarabi Z, Tavakkol‐Afshari J, et al. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow‐derived mesenchymal stem cells: a successful clinical trial in Iran. Biomed Pharmacother. 2019; 109: 1834‐ 1840. 30551438
  31. [32]Gao L, Zhang Y, Hu B, et al. Phase II multicenter, randomized, double‐blind controlled study of efficacy and safety of umbilical cord‐derived mesenchymal stromal cells in the prophylaxis of chronic graft‐versus‐host disease after HLA‐haploidentical stem‐cell transplantation. J Clin Oncol. 2016; 34(24): 2843‐ 2850. 27400949
  32. [33]Kong D, Zhuang X, Wang D, et al. Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus. Clin Lab. 2014; 60(12): 1969‐ 1976. 25651730
  33. [34]Weng J, He C, Lai P, et al. Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft‐versus‐host disease. Mol Ther. 2012; 20(12): 2347‐ 2354. 23070118 PMC3519994
  34. [35]Li X, Wang D, Liang J, et al. Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus. Bone Marrow Transplant. 2013; 48(4): 544‐ 550. 23064040
  35. [36]Xu L, Gong Y, Wang B, et al. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells. J Gastroenterol Hepatol. 2014; 29(8): 1620‐ 1628. 24942592
  36. [37]Fang XQ, Zhang JF, Song HY, et al. Effect of umbilical cord mesenchymal stem cell transplantation on immune function and prognosis of patients with decompensated hepatitis B cirrhosis. Zhonghua Gan Zang Bing Za Zhi. 2016; 24(12): 907‐ 910. 28073411 PMC12769450
  37. [38]Xiao Y, Jiang ZJ, Pang Y, et al. Efficacy and safety of mesenchymal stromal cell treatment from related donors for patients with refractory aplastic anemia. Cytotherapy. 2013; 15(7): 760‐ 766. 23731760
  38. [39]Detry O, Vandermeulen M, Delbouille MH, et al. Infusion of mesenchymal stromal cells after deceased liver transplantation: a phase I‐II, open‐label, clinical study. J Hepatol. 2017; 67(1): 47‐ 55. 28284916
  39. [40]Peng Y, Ke M, Xu L, et al. Donor‐derived mesenchymal stem cells combined with low‐dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation. 2013; 95(1): 161‐ 168. 23263506
  40. [41]Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol. 2011; 6(2): 412‐ 422. 20930086 PMC3052234
  41. [42]Soeder Y, Loss M, Johnson CL, et al. First‐in‐human case study: multipotent adult progenitor cells for immunomodulation after liver transplantation. Stem Cells Transl Med. 2015; 4(8): 899‐ 904. 26041737 PMC4511146
  42. [43]Keto J, Kaartinen T, Salmenniemi U, et al. Immunomonitoring of MSC‐treated GvHD patients reveals only moderate potential for response prediction but indicates treatment safety. Mol Ther Methods Clin Dev. 2018; 9: 109‐ 118. 29516024 PMC5834657
  43. [44]English K, Ryan JM, Tobin L, et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non‐redundant roles in human mesenchymal stem cell induction of CD4+CD25(high) forkhead box P3+ regulatory T cells. Clin Exp Immunol. 2009; 156(1): 149‐ 160. 19210524 PMC2673753
  44. [45]Lee HJ, Kim SN, Jeon MS, et al. ICOSL expression in human bone marrow‐derived mesenchymal stem cells promotes induction of regulatory T cells. Sci Rep. 2017; 7: 44486. 28290526 PMC5349520
  45. [46]Mota C, Nunes‐Silva V, Pires AR, et al. Delta‐like 1‐mediated notch signaling enhances the in vitro conversion of human memory CD4 T cells into FOXP3‐expressing regulatory T cells. J Immunol. 2014; 193(12): 5854‐ 5862. 25367118
  46. [47]Del Papa B, Sportoletti P, Cecchini D, et al. Notch1 modulates mesenchymal stem cells mediated regulatory T‐cell induction. Eur J Immunol. 2013; 43(1): 182‐ 187. 23161436
  47. [48]Cahill EF, Tobin LM, Carty F, et al. Jagged‐1 is required for the expansion of CD4+ CD25+ FoxP3+ regulatory T cells and tolerogenic dendritic cells by murine mesenchymal stromal cells. Stem Cell Res Ther. 2015; 6: 19. 25890330 PMC4414370
  48. [49]Rashedi I, Gomez‐Aristizabal A, Wang XH, et al. TLR3 or TLR4 activation enhances mesenchymal stromal cell‐mediated Treg induction via notch signaling. Stem Cells. 2017; 35(1): 265‐ 275. 27571579
  49. [50]Edwards JP, Thornton AM, Shevach EM. Release of active TGF‐beta1 from the latent TGF‐beta1/GARP complex on T regulatory cells is mediated by integrin beta8. J Immunol. 2014; 193(6): 2843‐ 2849. 25127859 PMC4157079
  50. [51]Hong JW, Lim JH, Chung CJ, et al. Immune tolerance of human dental pulp‐derived mesenchymal stem cells mediated by CD4(+)CD25(+)FoxP3(+) regulatory T‐cells and induced by TGF‐beta1 and IL‐10. Yonsei Med J. 2017; 58(5): 1031‐ 1039. 28792150 PMC5552631
  51. [52]Hsu WT, Lin CH, Chiang BL, et al. Prostaglandin E2 potentiates mesenchymal stem cell‐induced IL‐10+IFN‐gamma+CD4+ regulatory T cells to control transplant arteriosclerosis. J Immunol. 2013; 190(5): 2372‐ 2380. 23359497
  52. [53]Yang H, Sun J, Wang F, et al. Umbilical cord‐derived mesenchymal stem cells reversed the suppressive deficiency of T regulatory cells from peripheral blood of patients with multiple sclerosis in a co‐culture—a preliminary study. Oncotarget. 2016; 7(45): 72537‐ 72545. 27705922 PMC5341927
  53. [54]Tumangelova‐Yuzeir K, Naydenov E, Ivanova‐Todorova E, et al. Mesenchymal stem cells derived and cultured from glioblastoma multiforme increase Tregs, downregulate Th17, and induce the tolerogenic phenotype of monocyte‐derived cells. Stem Cells Int. 2019; 2019: 6904638. 31191680 PMC6525812
  54. [55]An JH, Song WJ, Li Q, et al. Prostaglandin E2 secreted from feline adipose tissue‐derived mesenchymal stem cells alleviate DSS‐induced colitis by increasing regulatory T cells in mice. BMC Vet Res. 2018; 14(1): 354. 30453939 PMC6245895
  55. [56]Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down‐regulate T cell receptor zeta‐chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006; 176(11): 6752‐ 6761. 16709834
  56. [57]Li X, Xu Z, Bai J, et al. Umbilical cord tissue‐derived mesenchymal stem cells induce T lymphocyte apoptosis and cell cycle arrest by expression of indoleamine 2, 3‐dioxygenase. Stem Cells Int. 2016; 2016: 7495135. 27418932 PMC4932168
  57. [58]He Y, Zhou S, Liu H, et al. Indoleamine 2, 3‐dioxgenase transfected mesenchymal stem cells induce kidney allograft tolerance by increasing the production and function of regulatory T cells. Transplantation. 2015; 99(9): 1829‐ 1838. 26308414
  58. [59]Mougiakakos D, Jitschin R, Johansson CC, et al. The impact of inflammatory licensing on heme oxygenase‐1‐mediated induction of regulatory T cells by human mesenchymal stem cells. Blood. 2011; 117(18): 4826‐ 4835. 21389316
  59. [60]Li JG, Zhuan‐sun YX, Wen B, et al. Human mesenchymal stem cells elevate CD4+CD25+CD127low/− regulatory T cells of asthmatic patients via heme oxygenase‐1. Iran J Allergy Asthma Immunol. 2013; 12(3): 228‐ 235. 23893806
  60. [61]Shen ZY, Wu B, Liu T, et al. Immunomodulatory effects of bone marrow mesenchymal stem cells overexpressing heme oxygenase‐1: protective effects on acute rejection following reduced‐size liver transplantation in a rat model. Cell Immunol. 2017; 313: 10‐ 24. 28069109
  61. [62]Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen‐G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells. 2008; 26(1): 212‐ 222. 17932417
  62. [63]Chen C, Liang J, Yao G, et al. Mesenchymal stem cells upregulate Treg cells via sHLA‐G in SLE patients. Int Immunopharmacol. 2017; 44: 234‐ 241. 28129605
  63. [64]Nasef A, Mazurier C, Bouchet S, et al. Leukemia inhibitory factor: role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol. 2008; 253(1–2): 16‐ 22. 18639869
  64. [65]Chen JY, Li CF, Kuo CC, et al. Cancer/stroma interplay via cyclooxygenase‐2 and indoleamine 2,3‐dioxygenase promotes breast cancer progression. Breast Cancer Res. 2014; 16(4): 410. 25060643 PMC4220086
  65. [66]Horita H, Kuroda E, Hachisuga T, et al. Induction of prostaglandin E2 production by leukemia inhibitory factor promotes migration of first trimester extravillous trophoblast cell line, HTR‐8/SVneo. Hum Reprod. 2007; 22(7): 1801‐ 1809. 17525067
  66. [67]Burr SP, Dazzi F, Garden OA. Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance? Immunol Cell Biol. 2013; 91(1): 12‐ 18. 23146942
  67. [68]Zhang B, Liu R, Shi D, et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged‐2‐dependent regulatory dendritic cell population. Blood. 2009; 113(1): 46‐ 57. 18832657
  68. [69]Zhao ZG, Xu W, Sun L, et al. Immunomodulatory function of regulatory dendritic cells induced by mesenchymal stem cells. Immunol Invest. 2012; 41(2): 183‐ 198. 21936678
  69. [70]Liu X, Qu X, Chen Y, et al. Mesenchymal stem/stromal cells induce the generation of novel IL‐10‐dependent regulatory dendritic cells by SOCS3 activation. J Immunol. 2012; 189(3): 1182‐ 1192. 22753940
  70. [71]Melief SM, Schrama E, Brugman MH, et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti‐inflammatory macrophages. Stem Cells. 2013; 31(9): 1980‐ 1991. 23712682
  71. [72]Chiossone L, Conte R, Spaggiari GM, et al. Mesenchymal stromal cells induce peculiar alternatively activated macrophages capable of dampening both innate and adaptive immune responses. Stem Cells. 2016; 34(7): 1909‐ 1921. 27015881
  72. [73]Cheung TS, Dazzi F. Mesenchymal‐myeloid interaction in the regulation of immunity. Semin Immunol. 2018; 35: 59‐ 68. 29395680
  73. [74]Rani S, Ryan AE, Griffin MD, et al. Mesenchymal stem cell‐derived extracellular vesicles: toward cell‐free therapeutic applications. Mol Ther. 2015; 23(5): 812‐ 823. 25868399 PMC4427881
  74. [75]Zhang B, Yin Y, Lai RC, et al. Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev. 2014; 23(11): 1233‐ 1244. 24367916
  75. [76]Zhang B, Yeo RWY, Lai RC, et al. Mesenchymal stromal cell exosome‐enhanced regulatory T‐cell production through an antigen‐presenting cell‐mediated pathway. Cytotherapy. 2018; 20(5): 687‐ 696. 29622483
  76. [77]Favaro E, Carpanetto A, Caorsi C, et al. Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients. Diabetologia. 2016; 59(2): 325‐ 333. 26592240
  77. [79]Naji A, Eitoku M, Favier B, et al. Biological functions of mesenchymal stem cells and clinical implications. Cell Mol Life Sci. 2019; 76(17): 3323‐ 3348. 31055643 PMC11105258
  78. [80]Weiss ARR, Dahlke MH. Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol. 2019; 10: 1191. 31214172 PMC6557979
  79. [81]Zheng G, Huang R, Qiu G, et al. Mesenchymal stromal cell‐derived extracellular vesicles: regenerative and immunomodulatory effects and potential applications in sepsis. Cell Tissue Res. 2018; 374(1): 1‐ 15. 29955951
  80. [82]Ramasamy R, Fazekasova H, Lam EW, et al. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. 2007; 83(1): 71‐ 76. 17220794
  81. [83]Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012; 12(5): 383‐ 396. 22531326
  82. [84]Romano M, Fanelli G, Albany CJ, et al. Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. Front Immunol. 2019; 10: 43. 30804926 PMC6371029
  83. [85]Caplan H, Olson SD, Kumar A, et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Front Immunol. 2019; 10: 1645. 31417542 PMC6685059
  84. [86]Weiss DJ, English K, Krasnodembskaya A, et al. The necrobiology of mesenchymal stromal cells affects therapeutic efficacy. Front Immunol. 2019; 10: 1228. 31214185 PMC6557974

Authors
Negi, N., & Griffin, M. D.
Affiliations
Ollscoil na Gaillimhe – University of Galway (IE)
Corresponding author
Griffin, Matthew D.
ORCID
Venue
Stem Cells
Publisher
Oxford University Press (OUP)
Published
2020-02-03
Volume
38
Issue
5
Pages
596-605
ISSN
  • 1066-5099 (ISSN-L)
  • 1549-4918
DOI
10.1002/stem.3151
PMC
PMC7217190
OpenAlex
W3003706822
Cited by
118
References
88
Citations by year
2026: 13 · 2025: 22 · 2024: 16 · 2023: 17 · 2022: 12 · 2021: 20 · 2020: 17 · 2019: 1
FWCI
8.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Stem Cells (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • ARAN (University of Galway Research Repository) (Ollscoil na Gaillimhe – University of Galway) (acceptedVersion, cc-by-nc-nd)
  • Arrow@dit (Dublin Institute of Technology) (acceptedVersion)
  • ARAN (University of Galway Research Repository) (Ollscoil na Gaillimhe – University of Galway) (submittedVersion, cc-by)
Funders
  • European Regional Development Fund (None)
  • FP7 Health (602470)
  • H2020 Health (634086)
  • H2020 Marie Skłodowska-Curie Actions (713690)
  • Science Foundation Ireland (09/SRC/B1794, 13/RC/2073)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords
mesenchymal stem cells, regulatory T cells, immunomodulation, exosomes, cell-cell contact, soluble factors, autoimmune disease, transplantation, cell therapy
MeSH terms
Animals, Humans, Immunotherapy, Models, Animal, T-Lymphocytes, Regulatory, Mice, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review